A June 11 decision from the Advertising Standards Authority, concerning one of Pfizer, Inc.’s IMEDEEN skin-care tablets, is a reminder that claims in the frontier nutricosmetics space are being monitored and must be substantiated with reliable scientific evidence.
The case concerns a regional press ad that ran in late 2012, promoting an unspecified IMEDEEN supplement that the brand claimed to “work from within to help reduce the appearance...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?